DRUG CHOICES BASED ON MANAGED CARE STUDIES IS A KEY ISSUE FOR FDA-AGENCY's ADAMS; QUESTIONS RAISED ON FULL DISCLOSURE IN INTERACTIVE MEDIA
The possibility of managed care organizations making drug treatment decisions based on their own studies "is going to be one of the main policy questions [FDA] is going to have to answer in the next few years," FDA Policy Development and Coordination Staff Director David Adams told the Regulatory Affairs Professionals Society March 1 in Chicago.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth